Imatinib Completed Phase 2 Trials for Acral/Lentiginous Melanoma / Chronically Sun Damaged Melanomas / Mucosal Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00424515Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma